Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 8;2023(1):216-222.
doi: 10.1182/hematology.2023000508.

Bispecific antibody therapies

Luiz Henrique de Assis  1 , Daniel El Fassi  2 , Martin Hutchings  2   3
Affiliations
Review

Bispecific antibody therapies

Luiz Henrique de Assis et al. Hematology Am Soc Hematol Educ Program. .

Abstract

Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles. The hematological toxicities are common and potentially harmful, and the side effects have hitherto not been reviewed. With many BsAbs recently approved and entering routine clinical use, we have reviewed the rather limited published data and propose recommendations on the management of these toxicities. Our review of the available data confirms that hematological toxicities are among the most common toxicities, with potentially harmful consequences for the patients. Fortunately, hemophagocytic lymphohystiocytosis and disseminated intravascular coagulation are rare. Severe neutropenia and hypogammaglobulinemia are manageable, and their timely treatment and prevention may reduce morbidity and mortality.

PubMed Disclaimer

Conflict of interest statement

Luiz Henrique de Assis: no competing financial interests to declare.

Daniel El Fassi: no competing financial interests to declare.

Martin Hutchings: honoraria: AbbVie, AstraZeneca, Celgene, Genmab, Janssen, Merck, Roche, and Takeda; research support (paid to the institution): AbbVie, AstraZeneca, Bristol Myers- Squibb, Celgene, Genentech, Genmab, Incyte, Janssen, Merck, Novartis, Roche, and Takeda.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Amhaz G, Bazarbachi A, El-Cheikh J.. Immunotherapy in indolent non- Hodgkin's lymphoma. Leuk Res Rep. 2022;17:100325. doi:10.1016/j.lrr.2022.100325. - DOI - PMC - PubMed
    1. Tian Z, Liu M, Zhang Y, Wang X.. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol OncolJ Hematol Oncol. 2021;14(1):75. doi:10.1186/s13045-021-01084-4. - DOI - PMC - PubMed
    1. Ludwig H, Terpos E, van de Donk N, et al.. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269. doi:10.1016/S1470-2045(23)00159-6. - DOI - PubMed
    1. Mohan M, Chakraborty R, Bal S, et al.. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. Preprint. Published online June 7, 2023. doi:10.1111/bjh.18909. - DOI - PMC - PubMed
    1. Salvaris R, Ong J, Gregory GP. Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas. J Pers Med. 2021;11(5):355.doi:10.3390/jpm11050355. - DOI - PMC - PubMed

Substances